Recombinant Protein Market to Reach US 4.25 Billion by 2030, Driven by Cell-Free Systems and Industrial Applications

Mordor Intelligence has published a new report on Recombinant Proteins market offering a comprehensive analysis of trends, growth drivers, and future projection

Introduction

The Recombinant Proteins market size is estimated at USD 2.9 billion in 2025 and is projected to climb to USD 4.25 billion by 2030, reflecting a steady 7.91 % CAGR.

Rapid uptake of protein-based therapeutics, wider acceptance of precision medicine, and expansion into food and industrial biotechnology underpin this forward momentum. An additional catalyst is the convergence of artificial intelligence with protein engineering, which is shortening design-to-clinic timelines and widening product pipelines. Higher throughput discovery tools are gradually lowering entry barriers for midsized companies, shifting the industry toward a more distributed innovation model. Continued regulatory clarity around biosimilars and interchangeable products is expected to smooth commercial pathways and accelerate time-to-revenue for late-stage assets.

Report Overview:

https://www.mordorintelligence.com/industry-reports/recombinant-protein-market?utm_source=openpr

Key Trends

Several critical factors are shaping this recombinant protein market's trajectory:

Rise of Protein-Based Therapeutics: Therapeutic proteins remain a major driver. Chronic disease prevalence and the increasing shift toward biologics and biosimilars are pushing pharma companies to develop and manufacture more recombinant proteins.

Accelerated Design with Cell-Free Systems: One of the fastest-growing areas is cell-free expression. These systems are projected to grow at around 8.72 % CAGR, offering much faster development cycles cutting production time from weeks to days and enabling the expression of proteins that are otherwise toxic or unstable in living cells.

Fusion Proteins & Bispecific Antibodies Gaining Ground: Fusion proteins and bispecific antibodies are among the fastest-growing product segments (about 8.43 % CAGR) because their multifunctional structure streamlines treatments and may improve patient adherence.

Cost Pressures & Biosimilar Competition: Although the market is expanding, high production costs remain a restraint, especially in mammalian cell culture. Moreover, biosimilars especially for insulin and erythropoietin are exerting downward pressure on prices.

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights:

https://www.mordorintelligence.com/ja/industry-reports/recombinant-protein-market?utm_source=openpr

Market Segmentation

The recombinant protein market can be broken down into several key segments, each reflecting different needs and growth dynamics:

Recombinant Protein Market Segmentation

By Product
• Hormones (Insulin, EPO, hGH, FSH)
• Cytokines & Growth Factors (ILs, CSFs, IFNs)
• Monoclonal Antibodies & Fragments
• Enzymes
• Fusion Proteins & Others

By Expression System
• Mammalian (CHO & HEK293)
• Bacterial (E. coli)
• Yeast (Pichia, Saccharomyces)
• Insect (Sf9, Sf21)
• Cell-Free / Synthetic

By Application
• Therapeutic
• Research
• Industrial (Agro-biotech, Food, Detergents)

By End User
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• CROs & CDMOs

By Geography

North America

South America

Europe

Middle east&Africa

Asia pacific

Key Players

Eli Lilly and Company

Thermo Fisher Scientific Inc.

Novartis AG

GlaxoSmithKline PLC

Pfizer Inc.

These key players leverage their scale, R&D capabilities, and manufacturing infrastructure to defend and grow their market share. At the same time, smaller or more nimble firms are differentiating themselves by focusing on newer platforms (for example, cell-free systems), licensing technologies, or partnering to accelerate market entry.

Conclusion

The recombinant protein market is poised for sustained growth through 2030, with a forecasted value of about US 4.25 billion, according to Mordor Intelligence. This rise will be driven by increasing demand for therapeutic proteins, the rapid adoption of cell-free expression systems, and diversification into industrial applications. While cost pressures from biosimilars and manufacturing hurdles remain, companies that adapt through technology innovation and efficient production are likely to capture significant opportunities. As the market continues to mature, ongoing developments in expression platforms and regulatory clarity will be key factors shaping the future of recombinant protein market growth.

For complete market analysis, please visit the Mordor Intelligence page:

https://www.mordorintelligence.com/industry-reports/recombinant-protein-market?utm_source=openpr

Industry related Reports:

Global Bone Morphogenetic Protein Market: The Bone Morphogenetic Protein Market is segmented by type, including Recombinant Human Bone Morphogenetic Protein (rhBMP)-2 and Recombinant Human Bone Morphogenetic Protein (rhBMP)-7; by application, covering spinal fusion, trauma, reconstructive surgery, and oral-maxillofacial procedures; and by geography, encompassing North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market analysis provides value estimates in USD million for all these segments.

Get more Insights : https://www.mordorintelligence.com/industry-reports/bone-morphogenetic-protein-market?utm_source=openpr

Proteinase K Market : The Global Proteinase K Market is segmented by product type natural and recombinant Proteinase K; by form, including lyophilised powder and liquid solution; by application, such as DNA/RNA extraction and purification, in-situ hybridisation, and other related uses; and by end users, including biotechnology and pharmaceutical companies, among others. The market is further categorized by geography, covering regions such as North America, Europe, and others, with values presented in USD million for all listed segments.

Get more Insights : https://www.mordorintelligence.com/industry-reports/proteinase-k-market?utm_source=openpr

Biopharmaceuticals Market : The Biopharmaceutical Industry Market is segmented by product type which includes monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, and more by therapeutic application such as oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic and hormonal disorders, among others, and by geography.

Get more Insights: https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-market-industry?utm_source=openpr



About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.